Niagen Bioscience Divests ChromaDex Reference Standards Business to LGC
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier B · Tier ceiling 89 · LONGIFI_SIGNAL_V1
Quick take
Niagen Bioscience has completed the all-cash sale of its ChromaDex Reference Standards business to LGC, streamlining its operations to focus resources exclusively on NAD+ science and product growth.
What happened
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced the sale of its ChromaDex Reference Standards business to LGC Standards, a division of LGC Group.
The transaction was completed as an all-cash deal as of February 24, 2026.
The divested division provides reference materials, research chemicals, and proficiency testing to laboratories and pharmaceutical manufacturers.
Why it matters
The divestiture marks a strategic transition for Niagen Bioscience to completely exit non-core services and prioritize capital allocation toward patented consumer and clinical longevity therapies.
CEO Rob Fried stated the transaction simplifies the corporate structure, allowing talent to focus on scaling patented Niagen solutions across clinical and retail channels.
The move provides LGC Standards with expanded North American commercial reach to support pharmaceutical and testing laboratory customers.
Market impact
The sale enables Niagen Bioscience to fully concentrate on its core NAD+ boosting products, primarily its Tru Niagen oral supplement line and its prescription-only Niagen Plus clinical IV and injectable line.
By eliminating the operational overhead of the analytical reference standards business, the company enhances its capacity to defend its extensive patent portfolio covering nicotinamide riboside (NR) and other NAD+ precursors.
What comes next
Watch for the expansion of Niagen Plus clinical distribution through U.S. FDA-registered 503B compounding outsourcing facilities and clinics.
Watch for updates on Niagen Bioscience's capital allocation and potential research and development investments funded by the cash proceeds of this transaction.
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- ChromaDex
Company development · TECHNOLOGY · COMMERCIAL · FINANCING
Niagen Bioscience, Inc. (formerly operating and listed as ChromaDex) is the seller in this transaction, divesting its legacy analytical reference standards business to focus on its proprietary nicotinamide riboside consumer and clinical portfolio.
- Metro International Biotech
Sector exposure · TECHNOLOGY · COMMERCIAL
Metro International Biotech operates in the same NAD+ precursor and biosynthesis field, developing pharmaceutical-grade NAD+ boosters for metabolic health, representing a primary clinical counterpart in the therapeutic landscape that Niagen Bioscience is prioritizing. (LONGEFI analysis)
Sources
- U.S. Securities and Exchange CommissionSEC_EDGAR:GLOBAL